1. Rogers SN, et al. Health-related quality of life and clinical function after primary surgery for oral cancer. Br J Oral Maxillofac Surg 2002 Feb;40(1):11-8.
2. Høxbroe Michaelsen S, et al. Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. Eur J Cancer 2017 Jun; 78:91-102.
3. 最新がん統計 : [ 国立がん研究センター ] がん情報サービス . https://ganjoho.jp/reg_stat/statistics/stat/summary.html, (参照 2019-09-16)
4. Clark M. A rationale for therapy of the N0 neck. Laryngoscope 1997;107:1294- 315.
5. P. Zbären, et al. Elective neck dissection for carcinomas of the oral cavity: occult metastases, neck recurrences, and adjuvant treatment of pathologically positive necks. Am J Surg 2006;191(6):756-760.
6. M.W. van den Brekel, et al. The incidence of micrometastases in neck dissection specimens obtained from elective neck dissections. Laryngoscope 1996;106(8);987- 991.
7. Li ‐ Jen Liao, et al. Analysis of sentinel node biopsy combined with other diagnostic tools in staging cN0 head and neck cancer: A diagnostic meta‐analysis. Head Neck 2016 Apr;38(4):628-34.
8. Colevas AD, Yom SS, Pfister DG, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw 2018;18(5):479-490.
9. Balasubramanian B, Pogozelski WK, Tullius TD. DNA strand breaking by the hydroxyl radical is governed by the accessible surface areas of the hydrogen atoms of the DNA backbone. Proc Natl Acad Sci U S A 1998;18;95:9738-43.
10. Isabelle V, Prévost C, Spotheim-Maurizot M et al. Radiation-induced damages in single- and double-stranded DNA. Int J Radiat Biol 1995;67:169-76.
11. Lowe SW, Schmitt EM, Smith SW et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
12. Hauer-Jensen M1, Denham JW, Andreyev HJ. Radiation enteropathy- pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol 2014;11:470-9.
13. Followill DS, Kester D, Travis EL. Histological changes in mouse colon after single- and split-dose irradiation. Radiat Res 1993;136:280-8.
14. Kan S, Chun M, Jin YM et al. A rat model for radiation-induced proctitis. J Korean Med Sci 2000;15:682-9.
15. Dirix P, Abbeel S, Vanstraelen B, et al. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose–effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2009;75:385-92.
16. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose–effect relationship. Radiother Oncol 2007;85:64-73.
17. Christianen ME, Schilstra C, Beetz I, et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. Radiother Oncol 2012;105:107-14.
18. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010;28:2732-8.
19. Nevens D, et al. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiother Oncol 2017 Feb;122(2):171-177.
20. Tribius S, et al. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer Treat Rev 2011 Nov;37(7):511-9.
21. Klein J, et al. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. Oral Oncol 2014 Apr;50(4):254-62.
22. Beadle BM, et al. Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis. Cancer 2014 Mar 1;120(5):702-10.
23. Maccomb WS, Fletcher GH. Planned combination of surgery and radiation intreatment of advanced primary head and neck cancers. Am J Roentgenol Radium Ther Nucl Med 1957;77:397-414.
24. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972;29:1446-9.
25. van den Brekel MW, Castelijns JA, Stel HV, Golding RP, Meyer CJ, Snow GB. Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol 1993;250:11-17.
26. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100:712-20.
27. de Bondt RB, Nelemans PJ, Bakers F, Casselman JW, Peutz-Kootstra C, Kremer B, et al. Morphological MRI criteria improve the detection of lymph node metastases in head and neck squamous cell carcinoma: multivariate logistic regression analysis of MRI features of cervical lymph nodes. Eur Radiol 2009;19:626-33.
28. Bosch S, et al. Patterns of recurrence in electively irradiated lymph node regions after definitive accelerated intensity modulated radiation therapy for head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2016;94:766-74.
29. Daan Nevens, et al. Recurrence patterns after a decreased dose of 40 Gy to the elective treated neck in head and neck cancer. Radiotherapy and Oncology 2017;123:419-423.
30. Gillison ML et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019 Jan 5;393(10166):40- 50.
31. Bauml JM, et al. Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data. Cancer 2019 Feb 1;125(3):406-415.
32. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
33. Mackie TR, ScrimgerJW and Battista JJ: A convolution method of calculating dose for 15-MV x rays. Med. Phys 1985;12:188-196.
34. Ahnesjö A: Collapsed cone convolution of radiant energy for photon dose calculation in heterogeneous media. Med. Phys 1989;16:577-592.
35. Ulmer W and Harder D: A Triple Gaussian Pencil Beam Model for Photon Beam Treatment Planning. Z. Med. Phys 1995;5:25-30.
36. Ulmer W, Harder D: Application of a Triple Gaussian Pencil Beam Model for Photon Beam Treatment Planning. Z. Med. Phys 1996;6:68- 74.
37. Vincent Grégoire, et al. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology 2014;110:172-181.
38. 大西 洋,唐沢 久美子,唐沢 克之: がん・放射線療法 2017 改定第 7 版,学研メディカル集潤社,東京都品川区, 2017;464–473,678-688.
39. 福村直樹: 放射線治療ガイドライン 2016 年版 第 3 版 金原出版株式会社, 東京都文京区湯島, 390.
40. Japan Society for Head and Neck Cancer Registry Committee: Report of head and neck cancer registry of Japan. Clinical statistics of registered patients,2002. Japanese Journal of Head and Neck Cancer 2006;32:15-34.
41. Bourhis J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006 Sep 2;368(9538):843-54.
42. Nguyen-Tan PF, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014 Dec 1;32(34):3858-66.
43. 高橋信次: <60> Co 回転照射法における新しい工夫. 臨床放射線 1960;5:563-658.
44. Brahme A: Optimization of stationary and moving beam radiation therapy techniques. Radiother Oncol 1988;12(2):129-40.
45. Nishi, T., Nishimura, Y., Shibata, T., et al, Volume and dosimetric changes and initial clinical experience of a two-step adaptive intensity modulated radiation therapy(IMRT)scheme for head and neck cancer. Radiother. Oncol 2013;106(1):85- 89.
46. Nishimura, Y., Shibata, T., Nakamatsu, K., et al. : A two-step intensity- modulated radiation therapy method for nasopharyngeal cancer ; The Kinki University experience. Jpn. J. Clin. Oncol 2010;40(2):130-138.
47. Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2000;46:1117- 11126.
48. Dok R, Kalev P, Van Limbergen EJ, Asbagh LA, Vázquez I, Hauben E, et al. P16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Cancer Res 2014;15:1739-51.
49. Rosenbaum PR. Observational studies. 2nd edition. New York: Springer- Verlag; 2002.
50. Ang KK, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010 Jul 1;363(1):24-35.
51. Zhang B, Mo Z, Du W, et al. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol 2015;51(11):1041-1046.
52. Spreafico A, Huang SH, Xu W, et al. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer 2016;67:174-182.
53. Nevens D, Duprez F, Daisne JF, et al. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiat Oncol 2017;122(2):171-177.
54. Shaikh T, Handorf EA, Murphy CT, Mehra R, Ridge JA, Galloway TJ. The impact of radiation treatment time on survival in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2016;96(5):967-975.
55. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant)chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiat Oncol 2006;78(3):236-244.
56. Pignon JP, Le Maitre A, Maillard E, Bourhis J, Mach-Nc Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC)−An update on 93 randomised trials and 17,346 patients. Radiot Oncol 2009;92(1):4-14.
57. Carde P, Lacal F. Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival. Radiat Oncol Biol Phys 1981 Jul;7(7):929-33.
58. Zhang B, et al. Intensity-modulated radiation therapy versus 2D-RT or 3D- CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol 2015 Nov;51(11):10411046.
59. Du T, et al. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. PLoS One 2019 Jul 10;14(7):e0219611.